Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide - Beyond Air

Next Previous
Drug Profile

Nitric oxide - Beyond Air

Alternative Names: AIT-BRO; AIT-CF; AIT-COPD; AIT-NTM; AIT-NV; AIT-RSV; AIT-WH; gaseous NO - Beyond Air; gNO - Beyond Air; iNO - Beyond Air™; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN; Ultra-High Concentration Nitric Oxide Therapy - Beyond Cancer; UNO therapy - Beyond Cancer

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Beyond Air; Schneider Childrens Medical Center of Israel; University of British Columbia
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections; Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchitis
  • Phase II Chronic obstructive pulmonary disease; COVID-19 pneumonia; Cystic fibrosis; Diabetic foot ulcer; Mycobacterial infections; Stroke
  • Phase I Solid tumours
  • No development reported COVID 2019 infections; Respiratory tract infections
  • Discontinued Asthma; Pneumonia

Most Recent Events

  • 12 Feb 2024 Beyond Air terminates phase I trial in Chronic obstructive pulmonary disease (Inhalation) prior to initiation
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Mycobacterial-infections in Australia (Inhalation)
  • 07 Nov 2023 Adverse events data from a phase I trial in Solid tumours released by Beyond Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top